Probabilistic Readjudication of Heart Failure Hospitalization Events in the PARAGON-HF Study

Circulation. 2021 Jun 8;143(23):2316-2318. doi: 10.1161/CIRCULATIONAHA.121.054496. Epub 2021 Jun 7.

Authors

G Michael Felker¹, Javed Butler², James L Januzzi Jr³, Akshay S Desai⁴, John J V McMurray⁵, Scott D Solomon⁴

Affiliations

¹ Duke Clinical Research Institute, Durham, NC (G.M.F.).
² University of Mississippi, Jackson (J.B.).
³ Massachusetts General Hospital, Boston (J.L.J.).
⁴ Brigham and Women's Hospital, Boston, MA (A.S.D., S.D.S.).
⁵ University of Glasgow, United Kingdom (J.J.V.M.).

PMID: 34097449
DOI: 10.1161/CIRCULATIONAHA.121.054496

No abstract available

Keywords: clinical trial; heart failure; hospitalization; probability; sacubitril-valsartan; valsartan.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aminobutyrates / pharmacology
Aminobutyrates / therapeutic use*
Biphenyl Compounds / pharmacology
Biphenyl Compounds / therapeutic use*
Clinical Trials, Phase III as Topic
Drug Combinations
Heart Failure / drug therapy*
Hospitalization / statistics & numerical data*
Humans
Probability
Stroke Volume / drug effects
Valsartan / pharmacology
Valsartan / therapeutic use*

Substances

Aminobutyrates
Biphenyl Compounds
Drug Combinations
Valsartan
sacubitril and valsartan sodium hydrate drug combination

Associated data

ClinicalTrials.gov/NCT01920711